Abbott (ABT) slips as results, guidance barely meet consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Abbott forecasts 2024 earnings largely below estimates, shares down
January 24, 2024 7:34 AM EST(Reuters) -Abbott Laboratories on Wednesday forecast 2024 profit largely below Wall Street estimates despite meeting quarterly earnings expectations, sending the medical device maker's shares down 2.5% in premarket trading.
Expectations around performance of medical device makers have increased over the last one month after health insurers flagged higher medical costs earlier this month as people, especially older adults, go back for medical procedures they had delayed during the pandemic.
Abbott's forecast also follows strong... More
Abbott (ABT) Reports In-Line Q4 EPS, Offers Guidance
January 24, 2024 7:31 AM ESTAbbott (NYSE: ABT) reported Q4 EPS of $1.19, in-line with the analyst estimate of $1.19. Revenue for the quarter came in at $10.24 billion versus the consensus estimate of $10.17 billion.
GUIDANCE:
Abbott sees FY2024 EPS of $4.50-$4.70, versus the consensus of $4.63.
For earnings history and earnings-related data on Abbott (ABT) click here.
... MoreAbbott Labs (ABT) PT Raised to $136 at UBS
January 22, 2024 7:52 AM ESTUBS analyst Danielle Antalffy raised the price target on Abbott Labs (NYSE: ABT) to $136.00 (from $122.00) while maintaining a Buy rating.... More
